Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$206.93M

FY 2025 · Annual

Net Income

-$190.89M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue114.09M156K95K22K0
Cost of Revenue014.3M0012.36M
Gross Profit114.09M(14.14M)95K22K(12.36M)
Gross Margin100.0%-9063.5%100.0%100.0%—
Research & Development220.18M256.39M242.91M192.3M150.15M
Selling, General & Admin74.11M79.31M71.67M65.21M56.78M
Operating Expenses294.28M321.4M327.83M273.22M194.57M
Depreciation & Amortization10.45M14.3M14.2M13.64M12.36M
EBITDA(171.6M)(326.12M)(313.07M)(243.33M)(177.45M)
EBITDA Margin-150.4%-209050.6%-329543.2%-1106031.8%—
Operating Income(180.19M)(335.54M)(327.74M)(273.2M)(206.93M)
Operating Margin-157.9%-215087.2%-344986.3%-1241813.6%—
Interest Income1.71M4.57M18.31M20.15M19.29M
Interest Expense000181K1.08M
Other Income / Expenses(1.86M)(4.88M)472K16.05M16.05M
Income Before Tax(182.05M)(340.41M)(327.27M)(257.15M)(190.89M)
Pre-Tax Margin-159.6%-218214.1%-344489.5%-1168850.0%—
Income Tax Expense000443K0
Net Income(182.05M)(340.41M)(327.27M)(257.59M)(190.89M)
Net Margin-159.6%-218214.1%-344489.5%-1170863.6%—
EPS (Basic)(1.34)(2.38)(2.09)(1.32)(0.87)
EPS (Diluted)(1.34)(2.38)(2.09)(1.32)(0.87)
Weighted Avg Shares135.82M143.15M156.93M194.81M220.62M
Weighted Avg Shares (Diluted)135.82M143.15M156.93M194.81M220.62M

ALLO Earnings Waterfall · TTM

NASDAQ:ALLO · Revenue to Net Income

Key Ratios

EPS$-0.77
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.1
P/S Ratio0.0

Analysis

$0 of revenue converted into -$173.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.77, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 6, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipOct 23, 2026

How much revenue does ALLO generate?

Allogene Therapeutics, Inc. (ALLO) reported $0.00 of revenue in fiscal 2025.

Is ALLO profitable?

Allogene Therapeutics, Inc. (ALLO) reported -$190.89M of net income.